Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 3/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 10/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789055 | 0.95 | CFD (0.33) | CFDMAPK1NMT1DPP4NMT2 | |
| SCHEMBL7897742 | 0.94 | CFD (0.34) | CFDMAPK1NMT1FEN1DPP4 | |
| SCHEMBL2788359 | 0.93 | CFD (0.33) | CFDMAPK1NMT1DPP4NMT2 | |
| SCHEMBL2790418 | 0.89 | CFD (0.35) | CFDFEN1DPP4DPP7DPP8 | |
| SCHEMBL2791666 | 0.87 | CFD (0.34) | CFDDPP4DPP7DPP8DPP9 | |
| SCHEMBL2791724 | 0.87 | CFD (0.34) | CFDDPP4DPP7DPP8DPP9 | |
| SCHEMBL2790905 | 0.87 | CFD (0.34) | CFDDPP4DPP7DPP8DPP9 | |
| SCHEMBL2791670 | 0.87 | CFD (0.34) | CFDDPP4DPP7DPP8DPP9 | |
| SCHEMBL2792686 | 0.84 | DPP4 (0.34) | CFDDPP4DPP7DPP8DPP9 | |
| SCHEMBL7898820 | 0.84 | DPP4 (0.35) | CFDMAPK1DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010111634-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |